ARIUS appoints Warren Whitehead as Chief Financial Officer

Dr. David S. Young appointed to President and Chief Executive Officer

TORONTO, Nov. 15 /CNW/ - ARIUS Research Inc. ("ARIUS") (TSX: ARI), today
announced the appointment of Warren Whitehead as Chief Financial Officer.
"We are very pleased to welcome Mr. Whitehead to ARIUS. He brings both a
wealth of capital markets experience and an extensive knowledge of the
biotechnology sector," said Dr. David S. Young, President and Chief Executive
Officer of ARIUS. "Warren will be a great addition to the leadership team as
we build on our strong momentum and move ARIUS to the next phase of growth."
Mr. Whitehead has held a number of senior financial management roles in
the industry, most recently as Chief Financial Officer of Labopharm Inc.,
where he lead several rounds of financing including a cross-border NASDAQ
offering. He held prior positions with Resolution Pharmaceuticals Inc. and
Glaxo Canada (now GSK). Mr. Whitehead is a Certified Management Accountant and
holds an MBA from the University of Windsor.
Catherine Auld who has been ARIUS' Interim Chief Financial Officer on a
part-time basis since May 2006 will continue to consult for the Company during
a transition phase.
"We would like to thank Ms. Auld for her considerable and invaluable
contributions to ARIUS during these past months, including leading our
graduation to the Toronto Stock Exchange," said Dr. Young.
In addition to Warren's appointment, the Board is very pleased to
announce the appointment of Dr. David S. Young, the founder of ARIUS, and the
Company's President and Chief Scientific Officer since inception, to President
and Chief Executive Officer.
"David has been instrumental in making ARIUS the company it is today and
we believe he is the right leader to take ARIUS through its next stage of
growth," said Dr. Carl Gordon, a member of the ARIUS Board of Directors.

About ARIUS
ARIUS Research Inc. is a biotechnology company dedicated to personalizing
cancer therapy through the discovery and development of novel anticancer
monoclonal antibodies (MAbs). Established in 1999, ARIUS has built a
proprietary technology platform, FunctionFIRST(TM), that rapidly identifies
powerful MAbs targeting a variety of cancer indications. This antibody
generation engine has enabled ARIUS to assemble a growing pipeline, which is
used for commercial collaborations and in-house development. ARIUS has ongoing
partnerships with key biotechnology and drug development companies. The
Company is listed on the TSX under the symbol "ARI".

Forward-Looking Statement
Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.

%SEDAR: 00013708E